EUVIMEDEUVIMED entdecken
Crossref

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

Yomna I El-Gazzar, Rasha Abdelhady iD, Nancy S Younis iD, Mervt Almostafa iD, Ahmed S Saad, Hanan H Georgey, Mona F Said

Archiv der Pharmazie · 2026

DOI: 10.1002/ardp.70186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Yomna I El-Gazzar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obour University for Science and Technology, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design, Protein Kinase Inhibitors, Quinazolinones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of novel quinazoline‐4‐one/chalcone hybrids ( 4a–4j ) were synthesized and evaluated as epidermal growth factor receptor (EGFR) inhibitors with anticancer activity. The target compounds were in vitro tested against MCF‐7 and HepG2 cancer cell lines, and the EGFR enzyme. Compounds 4a and 4g were the most potent EGFR inhibitors (IC 50 = 0.09 µM and 0.10 µM, respectively), compared to the standard erlotinib (IC 50 = 0.16 µM). Also, they exhibited anticancer activity against both cell lines. They were found to induce cell cycle arrest and apoptosis in MCF‐7 and HepG2 cancer cells. Molecular docking revealed that, compounds 4a and 4g bind to the active site of EGFR with the Lys A721 amino acid residue in a manner analogous to Erlotinib. This binding interaction likely contributes to their significant biological activity. Further, dynamic stimulation study that is conducted for compounds 4a and 4g , supports their potency as therapeutic agents in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug DesignProtein Kinase InhibitorsQuinazolinonesQuinazolinesChalconeHumansErbB ReceptorsStructure-Activity RelationshipMolecular Docking SimulationApoptosisDrug Screening Assays, AntitumorMolecular StructureCell ProliferationMCF-7 CellsDose-Response Relationship, DrugHep G2 CellsCell Cycle Checkpoints

Stichwörter der Autor:innen

ChalconeEGFR inhibitorsIn silico studiesQuinazoline‐4‐oneanticancer activity

Substanzen

ErbB ReceptorsAntineoplastic AgentsProtein Kinase InhibitorsEGFR protein, humanQuinazolinonesQuinazolinesChalcone

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obour University for Science and Technology, Cairo, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Egypt.
  • Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
  • Zagazig University Hospitals, Zagazig University, Zagazig, Egypt.
  • Department of Chemistry, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia.

ORCID-Profile: Rasha Abdelhady, Nancy S Younis, Mervt Almostafa

Zitieren

APA

El-Gazzar, Y. I., Abdelhady, R., Younis, N. S., Almostafa, M., Saad, A. S., Georgey, H. H., & Said, M. F. (2026). Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70186

Vancouver

El-Gazzar YI, Abdelhady R, Younis NS, Almostafa M, Saad AS, Georgey HH, et al. Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70186

BibTeX
@article{ElGazzar2026,
  author = {El-Gazzar, Yomna I and Abdelhady, Rasha and Younis, Nancy S and Almostafa, Mervt and Saad, Ahmed S and Georgey, Hanan H and Said, Mona F},
  title = {Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation},
  journal = {Archiv der Pharmazie},
  year = {2026},
  doi = {10.1002/ardp.70186}
}
Kostenlos starten →